Patents by Inventor Mwangi Wa Mutahi

Mwangi Wa Mutahi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperidine compounds
    Patent number: 7238688
    Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: July 3, 2007
    Assignee: Schering Corporation
    Inventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
  • Piperidine compounds
    Patent number: 6849621
    Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H. receptor antagonist.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: February 1, 2005
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.
    Inventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Patent number: 6762186
    Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: July 13, 2004
    Assignee: Schering Corporation
    Inventors: Neng-Yang Shih, Robert G. Aslanian, Daniel M. Solomon, Stuart B. Rosenblum, Mwangi Wa Mutahi, Tom G. Wing, Kevin D. McCormick, John J. Piwinski, Ronald Wolin
  • Novel non-imidazole compounds
    Publication number: 20030109564
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: March 11, 2002
    Publication date: June 12, 2003
    Applicant: Schering Corporation
    Inventors: Stuart B. Rosenblum, Qingbei Zeng, Mwangi Wa Mutahi, Robert G. Aslanian, Pauline C. Ting, Neng-Yang Shih, Daniel M. Solomon, Jianhua Cao, Henry A. Vaccaro, Kevin D. McCormick, John J. Baldwin, Ge Li
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Patent number: 6518287
    Abstract: The present invention discloses novel substituted imidazole compounds which have either or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: February 11, 2003
    Assignee: Schering Corporation
    Inventors: Robert G. Aslanian, Stuart Rosenblum, Mwangi Wa Mutahi, Neng-Yang Shih, John J. Piwinski
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Publication number: 20020103235
    Abstract: The present invention discloses novel substituted imidazole compounds which have either or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.
    Type: Application
    Filed: September 18, 2001
    Publication date: August 1, 2002
    Inventors: Robert G. Aslanian, Stuart B. Rosenblum, Mwangi Wa Mutahi, Neng-Yang Shih, John J. Piwinski
  • Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
    Publication number: 20020082278
    Abstract: The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.
    Type: Application
    Filed: September 18, 2001
    Publication date: June 27, 2002
    Inventors: Neng-Yang Shih, Robert G. Aslanian, Daniel M. Solomon, Stuart B. Rosenblum, Mwangi Wa Mutahi, Wing C. Tom, Kevin D. Mc Cormick, John J. Piwinski, Ronald Wolin